PET-CT use and the occurrence of elective nodal failure in involved field radiotherapy for non-small cell lung cancer: A systematic review

被引:11
作者
Kepka, Lucyna [1 ,2 ]
Socha, Joanna [3 ]
机构
[1] Minist Interior, Independent Publ Hlth Care Facil, Dept Radiat Oncol, PL-10228 Olsztyn, Poland
[2] Warmian & Mazurian Oncol Ctr, PL-10228 Olsztyn, Poland
[3] Reg Oncol Ctr, Dept Radiat Oncol, Czestochowa, Poland
关键词
Non-small cell lung cancer; PET-CT; Elective nodal failure; Involved-field radiotherapy; STEREOTACTIC BODY RADIOTHERAPY; MEDICALLY INOPERABLE PATIENTS; POSITRON-EMISSION-TOMOGRAPHY; DOSE CONFORMAL RADIOTHERAPY; PHASE-II TRIAL; STAGE-I; RADIATION-THERAPY; ABLATIVE RADIOTHERAPY; FDG-PET; IRRADIATION;
D O I
10.1016/j.radonc.2015.04.001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim: Current guidelines do not recommend the use of elective nodal irradiation for NSCLC, for several reasons. One of these is that PET-CT provides adequate nodal staging. We compared the published rates of elective nodal failures (ENFs) defined as regional failures that occur without local recurrence irrespectively of distant metastases status in patients who did or did not undergo PET-CT for staging. Methods: Reports of the occurrence of ENFs were considered. Only studies that used involved fields and specified the number of ENFs in patients with and without PET-CT use were included. A chi-squared test was used for the comparison of the risk of ENF in patients staged with and without PET. Results: Forty-eight studies were included; 2158 and 1487 patients with and without PET-CT performed before radiotherapy were identified. The proportion of patients treated with SBRT was higher in the group with PET-CT (71%) than it was in the group without PET-CT (20%; p < .001). There were 136 (6.3%) and 98 (6.6%) ENFs in patients with and without PET-CT, respectively (p = .74). Conclusion: The failure to reduce ENF by PET-CT was demonstrated. These data should be regarded in the context of the adequacy of reporting the rate of ENF and recognized value of PET-CT in NSCLC treatment. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:151 / 156
页数:6
相关论文
共 77 条
  • [1] Stereotactic radiotherapy of histologically proven inoperable stage I non-small cell lung cancer: Patterns of failure
    Andratschke, Nicolaus
    Zimmermann, Frank
    Boehm, Eva
    Schill, Sabine
    Schoenknecht, Christine
    Thamm, Reinhard
    Molls, Michael
    Nieder, Carsten
    Geinitz, Hans
    [J]. RADIOTHERAPY AND ONCOLOGY, 2011, 101 (02) : 245 - 249
  • [2] [Anonymous], 2014, NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer
  • [3] Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries
    Baumann, Pia
    Nyman, Jan
    Lax, Ingmar
    Friesland, Signe
    Hoyer, Morten
    Ericsson, Suzanne Rehn
    Johansson, Karl-Axel
    Ekberg, Lars
    Morhed, Elisabeth
    Paludan, Merete
    Wittgren, Lena
    Blomgren, Henrik
    Lewensohn, Rolf
    [J]. ACTA ONCOLOGICA, 2006, 45 (07) : 787 - 795
  • [4] Outcome in a Prospective Phase II Trial of Medically Inoperable Stage I Non-Small-Cell Lung Cancer Patients Treated With Stereotactic Body Radiotherapy
    Baumann, Pia
    Nyman, Jan
    Hoyer, Morten
    Wennberg, Berit
    Gagliardi, Giovanna
    Lax, Ingmar
    Drugge, Ninni
    Ekberg, Lars
    Friesland, Signe
    Johansson, Karl-Axel
    Lund, Jo-Asmund
    Morhed, Elisabeth
    Nilsson, Kristina
    Levin, Nina
    Paludan, Merete
    Sederholm, Christer
    Traberg, Anders
    Wittgren, Lena
    Lewensohn, Rolf
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (20) : 3290 - 3296
  • [5] Belderbos JSA, 2008, INT J RADIAT ONCOL, V72, P335, DOI 10.1016/j.ijrobp.2008.04.081
  • [6] Final results of a Phase I/II dose escalation trial in non-small-cell lung cancer using three-dimensional conformal radiotherapy
    Belderbos, Jose S. A.
    Heemsbergen, Wilma D.
    De Jaeger, Katrien
    Baas, Paul
    Lebesque, Joos V.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 66 (01): : 126 - 134
  • [7] SABR in NSCLC - The beginning of the end or the end of the beginning?
    Brada, Michael
    Pope, Anthony
    Baumann, Michael
    [J]. RADIOTHERAPY AND ONCOLOGY, 2015, 114 (02) : 135 - 137
  • [8] Toxicity and outcome results of RTOG 9311: A phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma
    Bradley, J
    Graham, MV
    Winter, K
    Purdy, JA
    Komaki, R
    Roa, WH
    Ryu, JK
    Bosch, W
    Emami, B
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 61 (02): : 318 - 328
  • [9] Elective nodal failures are uncommon in medically inoperable patients with Stage I non-small-cell lung carcinoma treated with limited radiotherapy fields
    Bradley, JD
    Wahab, S
    Lockett, MA
    Perez, CA
    Purdy, JA
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2003, 56 (02): : 342 - 347
  • [10] A PHASE II COMPARATIVE STUDY OF GROSS TUMOR VOLUME DEFINITION WITH OR WITHOUT PET/CT FUSION IN DOSIMETRIC PLANNING FOR NON-SMALL-CELL LUNG CANCER (NSCLC): PRIMARY ANALYSIS OF RADIATION THERAPY ONCOLOGY GROUP (RTOG) 0515
    Bradley, Jeffrey
    Bae, Kyounghwa
    Choi, Noah
    Forster, Ken
    Siegel, Barry A.
    Brunetti, Jacqueline
    Purdy, James
    Faria, Sergio
    Vu, Toni
    Thorstad, Wade
    Choy, Hak
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 82 (01): : 435 - 441